Nabiximols
2023P002959
Phase 2 small_molecule terminated
Quick answer
Nabiximols for NMO Spectrum Disorder is a Phase 2 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Jazz Pharmaceuticals plc
- Indication
- NMO Spectrum Disorder
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated